Boehringer Ingelheim

presented by
Policy

FDA will review angiotensin-receptor blockers (ARBs) for cancer risk

The Food and Drug Administration (FDA) has joined the ranks of public health agencies reviewing a popular class of blood pressure medicines and its possible link to cancer, despite criticism about using the method of meta-analysis to establish such a link. Researchers at Cleveland, Ohio’s, University Hospitals Harrington-McLaughlin Heart & Vascular Institute blew the whistle […]

News

Roxane, Ben Venue units settle Medicaid fraud claims for $7.75M

Two Ohio-based units of German drugmaker Boehringer Ingelheim will contribute to a $7.75 million settlement with Wisconsin of claims they overcharged its Medicaid program for drugs, according to the Pharmalot blog. The settlement by Roxane Laboratories in Columbus and Ben Venue Laboratories in Bedford — neither admitting wrongdoing or violation — was part of a […]

News

Ben Venue, Roxane parent launches $135M life sciences fund

The German parent of Ben Venue and Roxane drug-making facilities in Ohio has launched a $135 million venture fund to foster innovation in the life sciences. Boehringer Ingelheim GmbH of Ingelheim, Germany, started Boehringer Ingelheim Venture Fund to invest in biotech and start-up companies worldwide “that provide ground-breaking therapeutic approaches and technologies to help drive […]